IL17A and histiocytic sarcoma: Similarly, IL-1RA (anakinra) and anti-IL-1β antibodies (canakinumab), as well as IL-17 agents would be better suited for patients with HS with an IL1β-TH17 axis, rather than therapies aimed at lowering IL-12 or IL-23 expression (ustekinumab, and risankizumab and guselkumab, respectively) [26,40,108,109].